Recently, two anti-NLRP3 compounds, MCC95015 and β-hydroxybutyrate41, were shown to reduce the severity of NLRP3 inflammasome-mediated experimental autoimmune encephalomyelitis, Muckle-Wells syndrome, and autoinflammatory syndrome, etc. These findings further support that administration of a kidney-targeting shNLRP3 may be a potential therapeutic for IgAN. This evidence concerns the gene NLRP3 and Muckle-Wells syndrome.